Estrogen metabolism and risk of breast cancer in postmenopausal women

Journal of the National Cancer Institute

Volumn 104, Issue 4, 2012, Pages 326-339

  Fuhrman, Barbara J ^a   Schairer, Catherine ^a   Gail, Mitchell H ^a   Boyd Morin, Jennifer ^b   Xu, Xia ^c   Sue, Laura Y ^a   Buys, Saundra S ^d   Isaacs, Claudine ^e   Keefer, Larry K ^f   Veenstra, Timothy D ^c   Berg, Christine D ^a   Hoover, Robert N ^a   Ziegler, Regina G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b INFORMATION MANAGEMENT SERVICES INC   (United States)

^c SAIC FREDERICK INC   (United States)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTRONE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER INVASION; CANCER RISK; CANCER SCREENING; CASE CONTROL STUDY; COLORECTAL CANCER; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTROGEN BLOOD LEVEL; ESTROGEN METABOLISM; ESTRONE BLOOD LEVEL; FEMALE; HAZARD RATIO; HUMAN; HYDROXYLATION; LIQUID CHROMATOGRAPHY; LUNG CANCER; MAJOR CLINICAL STUDY; OVARY CANCER; POSTMENOPAUSE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; TANDEM MASS SPECTROMETRY;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHROMATOGRAPHY, LIQUID; CONFOUNDING FACTORS (EPIDEMIOLOGY); ESTRADIOL; ESTROGENS; ESTROGENS, CATECHOL; ESTRONE; FEMALE; HUMANS; HYDROXYESTRONES; HYDROXYLATION; METHYLATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, HORMONE-DEPENDENT; ODDS RATIO; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RISK ASSESSMENT; RISK FACTORS; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL;

EID: 84863243722     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr531     Document Type: Article

References (45)

1. Key T, Appleby P, Barnes I, Reeves G. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst. 2002; 94 (8): 606-616. (Pubitemid 34498648)
2. Ziegler RG, Rossi SC, Fears TR, et al. Quantifying estrogen metabolism: an evaluation of the reproducibility and validity of enzyme immunoassays for 2-hydroxyestrone and 16alpha-hydroxyestrone in urine. Environ Health Perspect. 1997; 105 (suppl 3): 607-614. (Pubitemid 27246424)
3. Adlercreutz H, Martin F. Biliary excretion and intestinal metabolism of progesterone and estrogens in man. J Steroid Biochem. 1980; 13 (2): 231-244. (Pubitemid 10079039)
4. Zhu BT, Han GZ, Shim JY, Wen Y, Jiang XR. Quantitative structure-activity relationship of various endogenous estrogen metabolites for human estrogen receptor alpha and beta subtypes: Insights into the structural determinants favoring a differential subtype binding. Endocrinology. 2006; 147 (9): 4132-4150. (Pubitemid 44274976)
5. Stack DE, Byun J, Gross ML, Rogan EG, Cavalieri EL. Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem Res Toxicol. 1996; 9 (5): 851-859.
6. Liehr JG. Dual role of oestrogens as hormones and pro-carcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prev. 1997; 6 (1): 3-10. (Pubitemid 27239511)
7. Chakravarti D, Mailander PC, Li KM, et al. Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene. 2001; 20 (55): 7945-7953. (Pubitemid 34001555)
8. Zahid M, Saeed M, Lu F, Gaikwad N, Rogan E, Cavalieri E. Inhibition of catechol-O-methyltransferase increases estrogen-DNA adduct formation. Free Radic Biol Med. 2007; 43 (11): 1534-1540. (Pubitemid 47615397)
9. Raftogianis R, Creveling C, Weinshilboum R, Weisz J. Estrogen metabolism by conjugation. J Natl Cancer Inst Monogr. 2000; (27): 113-124.
10. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med. 1986; 315 (21): 1305-1309. (Pubitemid 17030406)
11. Bradlow HL, Hershcopf R, Martucci C, Fishman J. 16 alpha-hydroxylation of estradiol: a possible risk marker for breast cancer. Ann N Y Acad Sci. 1986; 464: 138-151. (Pubitemid 17197628)
12. Cavalieri E, Rogan E. Catechol quinones of estrogens in the initiation of breast, prostate, and other human cancers: keynote lecture. Ann N Y Acad Sci. 2006; 1089: 286-301. (Pubitemid 47092096)
13. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med. 2006; 354 (3): 270-282.
14. Stanczyk FZ, Clarke NJ. Advantages and challenges of mass spectrometry assays for steroid hormones. J Steroid Biochem Mol Biol. 2010; 121 (3-5): 491-495.
15. Faupel-Badger JM, Fuhrman BJ, Xu X, et al. Comparison of liquid chromatography-tandem mass spectrometry, RIA, and ELISA methods for measurement of urinary estrogens. Cancer Epidemiol Biomarkers Prev. 2010; 19 (1): 292-300.
16. Xu X, Roman JM, Issaq HJ, et al. Quantitative measurement of endogenous estrogens and estrogen metabolites in human serum by liquid chromatography- tandem mass spectrometry. Anal Chem. 2007; 79 (20): 7813-7821. (Pubitemid 47622412)
17. Hayes RB, Sigurdson A, Moore L, et al. Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res. 2005; 592 (1-2): 147-154. (Pubitemid 41714051)
18. Lacey JV Jr., Kreimer AR, Buys SS, et al. Breast cancer epidemiology according to recognized breast cancer risk factors in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial Cohort. BMC Cancer. 2009; 9: 84.
19. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010; 304 (15): 1684-1692.
20. Tworoger SS, Hankinson SE. Collection, processing, and storage of biological samples in epidemiologic studies: sex hormones, carotenoids, inflammatory markers, and proteomics as examples. Cancer Epidemiol Biomarkers Prev. 2006; 15 (9): 1578-1581. (Pubitemid 44497089)
21. RTI, ed. SUDAAN User's Manual. Release. 8.0 ed. Research Triangle Park, NC: Research Triangle Institute; 2001.
22. Altekruse SF, Kosary CL, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute. http: //seer.cancer.gov/csr/1975-2007/. 2010. Accessed April 9, 2010. Based on November 2009 SEER data submission, posted to the SEER web site.
23. Kono S, Merriam GR, Brandon DD, Loriaux DL, Lipsett MB, Fujino T. Radioimmunoassay and metabolic clearance rate of catecholestrogens, 2-hydroxyestrone and 2-hydroxyestradiol in man. J Steroid Biochem. 1983; 19 (1B): 627-633.
24. Kabat GC, Chang CJ, Sparano JA, et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidemiol Biomarkers Prev. 1997; 6 (7): 505-509. (Pubitemid 27295229)
25. Ho GH, Luo XW, Ji CY, Foo SC, Ng EH. Urinary 2/16 alpha-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer risk. Ann Acad Med Singapore. 1998; 27 (2): 294-299. (Pubitemid 128518764)
26. Ursin G, London S, Stanczyk FZ, et al. Urinary 2-hydroxyestrone/16alpha- hydroxyestrone ratio and risk of breast cancer in postmenopausal women. J Natl Cancer Inst. 1999; 91 (12): 1067-1072. (Pubitemid 29293046)
27. Fowke JH, Qi D, Bradlow HL, et al. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection. Steroids. 2003; 68 (1): 65-72. (Pubitemid 35418304)
28. Kabat GC, O'Leary ES, Gammon MD, et al. Estrogen metabolism and breast cancer. Epidemiology. 2006; 17 (1): 80-88.
29. Meilahn EN, De Stavola B, Allen DS, et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br J Cancer. 1998; 78 (9): 1250-1255. (Pubitemid 28479160)
30. Muti P, Bradlow HL, Micheli A, et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2: 16alpha-hydroxyestrone ratio in premenopausal and postmenopausal women. Epidemiology. 2000; 11 (6): 635-640.
31. Cauley JA, Zmuda JM, Danielson ME, et al. Estrogen metabolites and the risk of breast cancer in older women. Epidemiology. 2003; 14 (6): 740-744. (Pubitemid 40417025)
32. Wellejus A, Olsen A, Tjonneland A, Thomsen BL, Overvad K, Loft S. Urinary hydroxyestrogens and breast cancer risk among postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev. 2005; 14 (9): 2137-2142. (Pubitemid 41603258)
33. Modugno F, Kip KE, Cochrane B, et al. Obesity, hormone therapy, estrogen metabolism and risk of postmenopausal breast cancer. Int J Cancer. 2006; 118 (5): 1292-1301. (Pubitemid 43185620)
34. Eliassen AH, Missmer SA, Tworoger SS, Hankinson SE. Circulating 2-hydroxy- and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2008; 17 (8): 2029-2035.
35. Arslan AA, Shore RE, Afanasyeva Y, Koenig KL, Toniolo P, Zeleniuch-Jacquotte A. Circulating estrogen metabolites and risk for breast cancer in premenopausal women. Cancer Epidemiol Biomarkers Prev. 2009; 18 (8): 2273-2279.
36. Falk RT, Rossi SC, Fears TR, et al. A new ELISA kit for measuring urinary 2-hydroxyestrone, 16alpha-hydroxyestrone, and their ratio: reproducibility, validity, and assay performance after freeze-thaw cycling and preservation by boric acid. Cancer Epidemiol Biomarkers Prev. 2000; 9 (1): 81-87. (Pubitemid 30062913)
37. Bransfield LA, Rennie A, Visvanathan K, et al. Formation of two novel estrogen guanine adducts and HPLC/MS detection of 4-hydroxyestradiol-N7-guanine in human urine. Chem Res Toxicol. 2008; 21 (8): 1622-1630.
38. Liehr JG, Avitts TA, Randerath E, Randerath K. Estrogen-induced endogenous DNA adduction: possible mechanism of hormonal cancer. Proc Natl Acad Sci USA. 1986; 83 (14): 5301-5305. (Pubitemid 16051363)
39. Zhu BT. Catechol-O-Methyltransferase (COMT)-mediated methylation metabolism of endogenous bioactive catechols and modulation by endobiotics and xenobiotics: importance in pathophysiology and pathogenesis. Curr Drug Metab. 2002; 3 (3): 321-349. (Pubitemid 34625043)
40. Mailander PC, Meza JL, Higginbotham S, Chakravarti D. Induction of A.T to G.C mutations by erroneous repair of depurinated DNA following estrogen treatment of the mammary gland of ACI rats. J Steroid Biochem Mol Biol. 2006; 101 (4-5): 204-215. (Pubitemid 44573805)
41. Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A. Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem. 1986; 24 (1): 353-356.
42. Cavalieri EL, Stack DE, Devanesan PD, et al. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci U S A. 1997; 94 (20): 10937-10942. (Pubitemid 27430839)
43. Zhao Z, Kosinska W, Khmelnitsky M, et al. Mutagenic activity of 4-hydroxyestradiol, but not 2-hydroxyestradiol, in BB rat2 embryonic cells, and the mutational spectrum of 4-hydroxyestradiol. Chem Res Toxicol. 2006; 19 (3): 475-479.
44. Crooke PS, Ritchie MD, Hachey DL, Dawling S, Roodi N, Parl FF. Estrogens, enzyme variants, and breast cancer: a risk model. Cancer Epidemiol Biomarkers Prev. 2006; 15 (9): 1620-1629. (Pubitemid 44497096)
45. Canzian F, Cox DG, Setiawan VW, et al. Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet. 2010; 19 (19): 3873-3884.